{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Thyroid+Gland+Carcinoma&page=4",
    "query": {
      "condition": "Metastatic Thyroid Gland Carcinoma",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 134,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Thyroid+Gland+Carcinoma&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Thyroid+Gland+Carcinoma&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T20:30:41.837Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00466856",
      "title": "Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Islet Cell Tumor",
        "Metastatic Cancer",
        "Pheochromocytoma"
      ],
      "interventions": [
        {
          "name": "octreotide acetate",
          "type": "DRUG"
        },
        {
          "name": "yttrium Y 90 resin microspheres",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2003-12",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2012-05-18",
      "last_synced_at": "2026-10-13T20:30:41.837Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00466856"
    },
    {
      "nct_id": "NCT02973997",
      "title": "Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Columnar Cell Variant Thyroid Gland Papillary Carcinoma",
        "Follicular Variant Thyroid Gland Papillary Carcinoma",
        "Metastatic Thyroid Gland Follicular Carcinoma",
        "Metastatic Thyroid Gland Papillary Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Follicular Carcinoma",
        "Recurrent Thyroid Gland Papillary Carcinoma",
        "Stage III Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage III Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage III Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7",
        "Tall Cell Variant Thyroid Gland Papillary Carcinoma",
        "Thyroid Gland Hurthle Cell Carcinoma",
        "Unresectable Differentiated Thyroid Gland Carcinoma",
        "Unresectable Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2018-02-07",
      "completion_date": "2023-10-08",
      "has_results": true,
      "last_update_posted_date": "2025-08-29",
      "last_synced_at": "2026-10-13T20:30:41.837Z",
      "location_count": 7,
      "location_summary": "Torrance, California • Aurora, Colorado • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02973997"
    },
    {
      "nct_id": "NCT01534897",
      "title": "Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Papillary Thyroid Carcinoma"
      ],
      "interventions": [
        {
          "name": "GSK2118436",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2012-07",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2017-03-15",
      "last_synced_at": "2026-10-13T20:30:41.837Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01534897"
    },
    {
      "nct_id": "NCT04467021",
      "title": "Cancer and Blood Pressure Management, CARISMA Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cardiovascular Disorder",
        "Chronic Kidney Disease",
        "Metastatic Renal Cell Carcinoma",
        "Metastatic Thyroid Gland Medullary Carcinoma",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IV Thyroid Gland Medullary Carcinoma AJCC v8",
        "Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8",
        "Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8",
        "Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Blood Pressure Measurement",
          "type": "OTHER"
        },
        {
          "name": "Clinical Management",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2020-10-29",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-13T20:30:41.837Z",
      "location_count": 25,
      "location_summary": "Creve Coeur, Missouri • St Louis, Missouri • The Bronx, New York + 18 more",
      "locations": [
        {
          "city": "Creve Coeur",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04467021"
    },
    {
      "nct_id": "NCT01413113",
      "title": "Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Thyroid Cancer",
        "Stage IVA Follicular Thyroid Cancer",
        "Stage IVA Papillary Thyroid Cancer",
        "Stage IVB Follicular Thyroid Cancer",
        "Stage IVB Papillary Thyroid Cancer",
        "Stage IVC Follicular Thyroid Cancer",
        "Stage IVC Papillary Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "pazopanib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "iodine I 131",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2011-12",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2015-11-05",
      "last_synced_at": "2026-10-13T20:30:41.837Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01413113"
    },
    {
      "nct_id": "NCT00390325",
      "title": "Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Thyroid Gland Medullary Carcinoma",
        "Locally Advanced Thyroid Gland Medullary Carcinoma",
        "Multiple Endocrine Neoplasia Type 2A",
        "Multiple Endocrine Neoplasia Type 2B",
        "Recurrent Thyroid Gland Medullary Carcinoma",
        "Sporadic Thyroid Gland Medullary Carcinoma",
        "Stage III Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2006-11-03",
      "completion_date": "2022-12-22",
      "has_results": true,
      "last_update_posted_date": "2024-02-06",
      "last_synced_at": "2026-10-13T20:30:41.837Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • Durham, North Carolina • Columbus, Ohio",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00390325"
    },
    {
      "nct_id": "NCT01624220",
      "title": "A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spinal Tumor"
      ],
      "interventions": [
        {
          "name": "Spinal SBRT (Standard Dose)",
          "type": "RADIATION"
        },
        {
          "name": "Spinal SBRT (Higher Dose)",
          "type": "RADIATION"
        },
        {
          "name": "Gold Seed Implantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2012-08-03",
      "completion_date": "2023-04-14",
      "has_results": true,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-10-13T20:30:41.837Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01624220"
    },
    {
      "nct_id": "NCT00061906",
      "title": "Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2003-01",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2014-02-11",
      "last_synced_at": "2026-10-13T20:30:41.837Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00061906"
    },
    {
      "nct_id": "NCT06991738",
      "title": "177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "68Ga-DOTA-TATE PET Scan",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Amino acid infusions",
          "type": "OTHER"
        },
        {
          "name": "177Lu-DOTA-EB-TATE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 18,
      "start_date": "2026-10-18",
      "completion_date": "2032-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-13T20:30:41.837Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06991738"
    },
    {
      "nct_id": "NCT00094055",
      "title": "Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Neoplasms"
      ],
      "interventions": [
        {
          "name": "AG013736",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2004-09",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2012-06-26",
      "last_synced_at": "2026-10-13T20:30:41.837Z",
      "location_count": 9,
      "location_summary": "Santa Monica, California • Aurora, Colorado • Denver, Colorado + 5 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00094055"
    }
  ]
}